Sign in
Not yet taking people in United StatesPhase 2

Methylphenidate and Response to Alcohol Cues

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
Oct 2026
Expected to end
Aug 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Methylphenidate Pill
  • Placebo Pill
Record updated
20 August 2026

Who can take part

Age
18 years to 25 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Adults ages 18-25 years
  • Meets DSM-5 criteria for Alcohol Use Disorder -OR- score on the Alcohol Use Disorders Identification Test (AUDIT) of >=8
  • Fluent in English
  • Normal or corrected to normal vision

Who cannot take part

  • Meets DSM-5 criteria for psychotic disorders, neurological disorders, or substance use disorders other than Alcohol Use Disorder
  • Participant routinely uses psychoactive drugs or medications except for non-dependent marijuana or nicotine use (due to common use of these substances in individuals with Alcohol Use Disorder)
  • Self-reported history of high blood pressure over 140/90 or consistent readings of 140/90 or above upon arrival for a session
  • History of seizure disorder
  • Liver disease
  • Participant has contraindications for taking methylphenidate
  • Participant has contraindications for being in an MRI machine
  • Participant is currently pregnant or trying to become pregnant

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 25 years old?

Where in United States

  • University of FloridaGainesville, United StatesContact: Amanda Elton, PhDNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin, affects responses to alcohol cues. The study will observe the effects of methylphenidate or a placebo on neural and craving responses to alcohol cues through fMRI and behavioral testing. Participants will be involved in one remote and two in-person sessions.

The 2 groups in the trial

  • Crossover 1: methylphenidate, placeboTreatment being tested

    methylphenidate (single dose, oral, 20 mg, immediate release) followed by placebo (single dose, oral)

    Treatment: Methylphenidate Pill and Placebo Pill

  • Crossover 2: placebo, methylphenidateTreatment being tested

    placebo (single dose, oral) followed by methylphenidate (single dose, oral, 20 mg, immediate release)

    Treatment: Methylphenidate Pill and Placebo Pill

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Attentional Ability and Resilience to Alcohol Use Disorder: Neurocognitive Mechanisms: Protocol Two
Fit questions
Built from NCT07306078, who can take part
Record updated
20 August 2026